<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/293BE4EA-B28B-4D89-A4D0-D5F6349AC6C4"><gtr:id>293BE4EA-B28B-4D89-A4D0-D5F6349AC6C4</gtr:id><gtr:name>Randox Laboratories</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3060B2EB-B5DB-4520-A2B4-5751D1ABAB38"><gtr:id>3060B2EB-B5DB-4520-A2B4-5751D1ABAB38</gtr:id><gtr:name>Affymetrix</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/27A00057-D57C-421A-B681-A369CEE309E9"><gtr:id>27A00057-D57C-421A-B681-A369CEE309E9</gtr:id><gtr:name>Blackrock Microsystems LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/29A671C9-96A0-4955-B890-76F05D83EE0D"><gtr:id>29A671C9-96A0-4955-B890-76F05D83EE0D</gtr:id><gtr:name>Medtronic</gtr:name><gtr:address><gtr:line1>710 Medtronic Parkway</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/620DB27D-4014-4278-AAD1-11105CC6BDEA"><gtr:id>620DB27D-4014-4278-AAD1-11105CC6BDEA</gtr:id><gtr:name>Novo Nordisk</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C1E0E310-885F-4DC7-B908-31AACD12FAFA"><gtr:id>C1E0E310-885F-4DC7-B908-31AACD12FAFA</gtr:id><gtr:name>Boehringer Ingelheim</gtr:name><gtr:address><gtr:line1>Corporate Division Communications</gtr:line1><gtr:line2>Binger Strasse 173</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/293BE4EA-B28B-4D89-A4D0-D5F6349AC6C4"><gtr:id>293BE4EA-B28B-4D89-A4D0-D5F6349AC6C4</gtr:id><gtr:name>Randox Laboratories</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3060B2EB-B5DB-4520-A2B4-5751D1ABAB38"><gtr:id>3060B2EB-B5DB-4520-A2B4-5751D1ABAB38</gtr:id><gtr:name>Affymetrix</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/27A00057-D57C-421A-B681-A369CEE309E9"><gtr:id>27A00057-D57C-421A-B681-A369CEE309E9</gtr:id><gtr:name>Blackrock Microsystems LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/29A671C9-96A0-4955-B890-76F05D83EE0D"><gtr:id>29A671C9-96A0-4955-B890-76F05D83EE0D</gtr:id><gtr:name>Medtronic</gtr:name><gtr:address><gtr:line1>710 Medtronic Parkway</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/620DB27D-4014-4278-AAD1-11105CC6BDEA"><gtr:id>620DB27D-4014-4278-AAD1-11105CC6BDEA</gtr:id><gtr:name>Novo Nordisk</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1E0E310-885F-4DC7-B908-31AACD12FAFA"><gtr:id>C1E0E310-885F-4DC7-B908-31AACD12FAFA</gtr:id><gtr:name>Boehringer Ingelheim</gtr:name><gtr:address><gtr:line1>Corporate Division Communications</gtr:line1><gtr:line2>Binger Strasse 173</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B5B6DAE2-3E16-4C20-86AD-77725C9EEE73"><gtr:id>B5B6DAE2-3E16-4C20-86AD-77725C9EEE73</gtr:id><gtr:firstName>Caroline</gtr:firstName><gtr:surname>Quest</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/ECF22327-6842-49CB-A398-31B6AAD9B89A"><gtr:id>ECF22327-6842-49CB-A398-31B6AAD9B89A</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Tobin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/775E1533-901D-47C8-953C-C9172D318B65"><gtr:id>775E1533-901D-47C8-953C-C9172D318B65</gtr:id><gtr:firstName>Phil</gtr:firstName><gtr:surname>Baker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_15056"><gtr:id>1D973C22-EA04-4817-B996-8E3CCB76EE74</gtr:id><gtr:title>?INDUSTRY PARTNERS FOR ALL? PROGRAMME ? Building the Foundation for Pharmaceutical and Biotech Industry Engagement at the University of Leicester</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_15056</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills.&amp;nbsp; The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers? understanding of each other?s needs and capabilities.&amp;nbsp; This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ?entrepreneurs in residence? schemes.&amp;nbsp; Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.</gtr:technicalSummary><gtr:fund><gtr:end>2017-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>150000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Boehringer Ingelheim</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Leicester Diabetes Centre and Boehringer Ingelheilm on renal outcomes in diabetes</gtr:description><gtr:id>84CD2265-ED00-44DD-8601-8DBB0E936C6A</gtr:id><gtr:impact>Signed contracts. To start in April 2017</gtr:impact><gtr:outcomeId>58cc031545ffd6.21562699-1</gtr:outcomeId><gtr:partnerContribution>Boehringer will provide expertise and access to the UK Clinical Practice Research Datalink (CPRD) database to run the project.</gtr:partnerContribution><gtr:piContribution>This is a secondment project. We have provided collaboration framework and covered travel and accommodation expenses for one PI from Leicester Diabetes Centre to travel and stay at Boehringer Ingelheilm to use their resources and databases.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Leicester Diabetes Centre and GSK on EMIF (European Medical Information Project) project</gtr:description><gtr:id>E6BB9223-7725-4393-9453-574ECE869879</gtr:id><gtr:impact>Signed contracts. To start in April 2017</gtr:impact><gtr:outcomeId>58cc04f58909b7.20577302-1</gtr:outcomeId><gtr:partnerContribution>GSK will provide expertise and access to the EMIF database to run the project.</gtr:partnerContribution><gtr:piContribution>This is a secondment project. We have provided collaboration framework and covered travel and accommodation expenses for one PI from Leicester Diabetes Centre to travel and stay at GSk to use the EMIF resources and databases.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Blackrock Microsystems LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>University of Leicester and Blackrock Microsystems on a new generation of portable and digital acquisition systems for 24/7 human electrophysiology.</gtr:description><gtr:id>7031BDFA-F066-4055-86A4-B0B082694714</gtr:id><gtr:impact>Signed contracts. To start in April 2017</gtr:impact><gtr:outcomeId>58cc0b2a2c2337.34175312-1</gtr:outcomeId><gtr:partnerContribution>BM will provide access to resources and software.</gtr:partnerContribution><gtr:piContribution>This is a secondment project. We have provided collaboration framework and covered travel and accommodation expenses for PI and postdoc (Centre for Systems Neurosciences) to travel and stay at Blackrock Microsystems subsidiary in Germany to develop relationships and generate a new generation of portable and digital acquisition systems for 24/7 human electrophysiology.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novo Nordisk</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>Leicester Diabetes Centre and Novo Nordisk on Beta blockers effects on the association of hypoglycemia with cardiovascular mortality.</gtr:description><gtr:id>3D32403B-D5EF-427F-83BA-85BB933CB3C2</gtr:id><gtr:impact>Signed contracts. To start in May 2017</gtr:impact><gtr:outcomeId>58cc04396a9d75.53006709-1</gtr:outcomeId><gtr:partnerContribution>Novo Nordisk will provide expertise and access to the UK Clinical Practice Research Datalink (CPRD) database to run the project.</gtr:partnerContribution><gtr:piContribution>This is a secondment project. We have provided collaboration framework and covered travel and accommodation expenses for one PI from Leicester Diabetes Centre to travel and stay at Novo Nordisk to use their resources and databases.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Randox Laboratories</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Randox collaboration in disease diagnosis</gtr:description><gtr:id>5C803046-A00B-400D-8BEF-20C28B652A42</gtr:id><gtr:impact>Outputs - potential commercialisation of diagnostic tools using Randox technology</gtr:impact><gtr:outcomeId>58cc000487e7a6.85885430-1</gtr:outcomeId><gtr:partnerContribution>Several visits from Randox members to our premises and an event programmed after Easter between KOL in Leicester and Research leaders at Randox</gtr:partnerContribution><gtr:piContribution>Engaging with Randox in a collaborative partnership to tap into Leicester's expertise in biomarker development for cardiovascular, respiratory and cancer.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>University of Leicester and AstraZeneca Open Innovation platform</gtr:description><gtr:id>A6190766-CBFF-477C-B58D-BB6A6B5F6EB7</gtr:id><gtr:impact>Signed contracts. To start in April 2017</gtr:impact><gtr:outcomeId>58cc0c3d2d8fd7.71764654-1</gtr:outcomeId><gtr:partnerContribution>AZ will contribute in the screening of approximately 50,000 pre-selected compounds.</gtr:partnerContribution><gtr:piContribution>This is a secondment project. We have provided collaboration framework and covered reagents, travel and accommodation expenses for a PI from University of Leicester to develop the right assays to screen approximately 50,000 pre-selected compounds targeted towards Kinase inhibition for screening to identify Nek8 inhibitors and understand potential mechanisms of action of Nek8 inhibitors in cancer cells.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johnson &amp; Johnson</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Biosense Webster</gtr:department><gtr:description>University of Leicester and Biosense Webster Inc. on improving efficacy of catheter ablation for atrial fibrillation</gtr:description><gtr:id>A043A6D3-D536-4316-89A1-BE0EF03CD357</gtr:id><gtr:impact>Signed contracts. To start in May 2017</gtr:impact><gtr:outcomeId>58cc12a22a1a95.23108436-1</gtr:outcomeId><gtr:partnerContribution>BWI would provide the equipment and catheters and the expenses required for the animal experiments.</gtr:partnerContribution><gtr:piContribution>This is a secondment project. We have provided collaboration framework and covered travel and accommodation expenses for one PI from Leicester Cardiovascular Department to travel and stay at Biosense Webster in US to run few experiments and use their expertise and resources.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Affymetrix</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>University of Leicester and Affymetrix to develop a bioinformatics and statistical analyses workflow to analyse Affymetrix Human Transcriptome Array.</gtr:description><gtr:id>803CEA38-DF31-4043-9FD6-A915EB34459F</gtr:id><gtr:impact>Signed contracts. To start in April 2017</gtr:impact><gtr:outcomeId>58cc0d451b3a32.47085633-1</gtr:outcomeId><gtr:partnerContribution>Allowing secondment and provide expertise and resources</gtr:partnerContribution><gtr:piContribution>This is a secondment project. We have provided collaboration framework and covered travel and accommodation expenses for a PI from Leicester Cardiovascular Department to travel and stay at Affymetrix HQ in USA to set up a new collaboration, use their resources and learn from their expertise.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medtronic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>University of Leicester and Medtronic collaboration on DRG (Dorsal Root Ganglion) modulation in preventing ventricular arrhythmias</gtr:description><gtr:id>105C0954-46B6-47A1-ABC8-CE29440D2A5F</gtr:id><gtr:impact>Signed contracts. To start in April 2017</gtr:impact><gtr:outcomeId>58cc11cb710c62.62148692-1</gtr:outcomeId><gtr:partnerContribution>Medtronic will offer resources and expertise at their site. They will also come to Leicester to develop IT packages to analyse the clinical data of CT and MRI scans from Leicester which will inform development of translational strategies to deliver a clinical effective treatment based on the novel preclinical mechanistic data.</gtr:partnerContribution><gtr:piContribution>This is a secondment project. We have provided collaboration framework and covered travel and accommodation expenses for one PI and his PhD from Leicester Cardiovascular Department to travel and stay at Medtronic in Netherlands to run few experiments and use their expertise and resources.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BioHomecoming 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DE1FD1BF-0ADB-4B17-B54A-7A598D11BF41</gtr:id><gtr:impact>http://www2.le.ac.uk/news/blog/2016-archive/october/industry-and-academia-build-links-in-precision-medicine-and-drug-discovery

The University of Leicester hosted an event bringing together industry and academic in fruitful discussions on drug discovery and precision medicine.
It was hosted at the Leicester Tigers Conference Centre and attended by over 300 delegates, 170 of which were industry delegates from the Pharma and Biotechnology sectors, including alumni, regional contacts and current collaborators of the University of Leicester.

Dr Ismael Tejero, Business Development Manager for the College of Medicine and main organiser of the event, said: &amp;quot;We managed to advertise our expertise and scientific offer, including our two new Research Institutes of Precision Medicine and Structural and Chemical Biology, to a broad range of delegates in the biomedical industry.

&amp;quot;The environment created during the Bio-Homecoming event really encouraged our academics to successfully establish and develop relationships with industrial peers across the country but also from Ireland and Switzerland. With more than 25 exhibitors and 600 scheduled one-to-one meetings, this event has started big and there is already a lot of interest and expectation to see the agenda for the Bio-homecoming 2017.&amp;quot;

Feedback from the event was very positive, with many commenting on the networking value of the one-to-one sessions.

Professor Philip Baker (pictured left), Dean of Medicine at the University of Leicester, said: &amp;quot;The interaction of clinicians and scientists from our College - with industry partners, generated a tremendous buzz. We are absolutely serious about strengthening and enhancing the synergies between academia and industry - in order to ensure that our research discoveries translate to public and patient benefit.&amp;quot;

Ian Cox from Idaco Consulting said: &amp;quot;I attend a lot of partnering events and this one was extremely well organised and run. The venue was ideal (even though I support Northampton Saints.), a good blend of talks and exhibitors, and the partnering meetings worked really well. Catering facilities were excellent. All in all a very enjoyable day. It was great to finally see what Leicester has to offer and I hope this event becomes an annual event because it will certainly increase and improve the University's visibility.&amp;quot;</gtr:impact><gtr:outcomeId>58cc1861edc6c8.38703887</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://www.biohomecoming.com/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_15056</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>